ReviewFrontiers in immunology2025
Cytokines unveiled: their impact on oral and multisystem features of lupus erythematosus.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- An Observational Case-Control Study of the Anti-Inflammatory Effects of Bromelain on Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus.Mediterranean journal of rheumatology · 2026Article
- Gene Expression Profiles in the Optic Nerve of Mice with Systemic Acanthamoebiasis.International journal of molecular sciences · 2026Article
- Pathogenic and Clinical Relevance of Serum IL-17A and TNF-α in Systemic Lupus Erythematosus.International journal of molecular sciences · 2026Article
- Immunopathogenesis of accelerated atherosclerosis in systemic lupus erythematosus: from innate and adaptive dysregulation to clinical implications.Frontiers in immunology · 2026Review
- Mechanisms of inflammation in premature ovarian insufficiency and advances in therapeutic studies.Frontiers in immunology · 2026Review
- Using the Immune System for Effective Periodontal and Caries Management.BioMed research international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic Lupus Erythematosus (SLE) is a multifaceted autoimmune disorder characterized by widespread inflammation and immune dysregulation, impacting various organ systems and generating autoantibodies. Oral lesions are a common and distressing manifestation of SLE, significantly affecting patients' quality of life. Cytokines, key mediators of immune responses, play a crucial role in the pathogenesis of both systemic and oral manifestations of SLE. This review sheds the light on current research on the involvement of various cytokines, including interleukins different interferon types, and growth factors in SLE. The intricate interplay between pro-inflammatory and anti-inflammatory cytokines contributes to the disease's initiation, progression, and diverse clinical presentations. Elevated levels of pro-inflammatory cytokines exacerbate inflammation, promote apoptosis, and drive autoantibody production. Understanding the specific roles of these cytokines offers potential therapeutic targets for managing SLE and improving patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.